Patents by Inventor Ann Hellstrom

Ann Hellstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treatment of complications of prematurity comprising administration of IGF-I and IGFBP-3
    Patent number: 9463222
    Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, said combination having a molar ratio of IGF-I to IGFBP 5 being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: October 11, 2016
    Assignee: PREMACURE AB
    Inventors: Ann Hellstrom, Chatarina Lofqvist, Lois Smith
  • METHOD AND PRODUCT FOR TREATMENT AND/OR PREVENTION OF COMPLICATIONS OF PREMATURITY
    Publication number: 20150216943
    Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, said combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.
    Type: Application
    Filed: February 9, 2015
    Publication date: August 6, 2015
    Applicant: PREMACURE AB
    Inventors: Ann Hellstrom, Chatarina Lofqvist, Lois Smith
  • METHOD AND PRODUCT FOR TREATMENT AND/OR PREVENTION OF COMPLICATIONS OF PREMATURITY
    Publication number: 20130310316
    Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, said combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: Premacure AB
    Inventors: Ann Hellstrom, Chatarina Lofqvist, Lois Smith
  • Method and product for treatment and/or prevention of complications of prematurity
    Patent number: 8518877
    Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, such combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: August 27, 2013
    Assignee: Premacure AB
    Inventors: Ann Hellstrom, Chatarina Lofqvist, Lois Smith
  • Methods for decreasing risk of complications of prematurity using IGF-I and its analogs
    Patent number: 7776820
    Abstract: In one aspect of the present invention there is provided a method for determining the risk of developing a complication of preterm birth in a patient born before 40 weeks of gestation or weighing 10% less than the average for the patient's gestational age. The method involves measuring serum IGF-I and/or IGF-I binding protein levels after birth of the patient to obtain an IGF-I or IGF-I binding protein level; and correlating said IGF-I or IGF-I binding protein level with an in utero baseline level of IGF-I or IGF-I binding protein based on gestational age matched mean levels in utero, wherein an IGF-I or IGF-I binding protein level below the mean gestational age in utero level indicates the patient is at an increased risk of developing a complication of preterm birth. The complications of preterm birth include retinopathy of prematurity, developmental delay, mental retardation, bronchopulmonary dysplasia, and intraventricular hemorrhage.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: August 17, 2010
    Assignee: Children's Medical Center Corporation
    Inventors: Lois E. H. Smith, Ann Hellström
  • METHOD AND PRODUCT FOR TREATMENT AND/OR PREVENTION OF COMPLICATIONS OF PREMATURITY
    Publication number: 20100204101
    Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, said combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.
    Type: Application
    Filed: April 18, 2008
    Publication date: August 12, 2010
    Applicant: Premacure AB
    Inventors: Ann Hellstrom, Chatarina Lofqvist, Lois Smith
  • Determination of risk and treatment of complications of prematurity
    Publication number: 20070196857
    Abstract: In one aspect of the present invention there is provided a method for determining the risk of developing a complication of preterm birth in a patient born before 40 weeks of gestation or weighing 10% less than the average for the patient's gestational age. The method involves measuring serum IGF-I and/or IGF-I binding protein levels after birth of the patient to obtain an IGF-I or IGF-I binding protein level; and correlating said IGF-I or IGF-I binding protein level with an in utero baseline level of IGF-I or IGF-I binding protein based on gestational age matched mean levels in utero, wherein an IGF-I or IGF-I binding protein level below the mean gestational age in utero level indicates the patient is at an increased risk of developing a complication of preterm birth. The complications of preterm birth include retinopathy of prematurity, developmental delay, mental retardation, bronchopulmonary dysplasia, and intraventricular hemorrhage.
    Type: Application
    Filed: September 14, 2006
    Publication date: August 23, 2007
    Applicant: Children's Medical Center Corporation
    Inventors: Lois Smith, Ann Hellstrom
  • Determination of risk and treatment of complications of prematurity
    Patent number: 7144707
    Abstract: In one aspect of the present invention there is provided a method for determining the risk of developing a complication of preterm birth in a patient born before 40 weeks of gestation or weighing 10% less than the average for the patient's gestational age. The method involves measuring serum IGF-I and/or IGF-I binding protein levels after birth of the patient to obtain an IGF-I or IGF-I binding protein level; and correlating said IGF-I or IGF-I binding protein level with an in utero baseline level of IGF-I or IGF-I binding protein based on gestational age matched mean levels in utero, wherein an IGF-I or IGF-I binding protein level below the mean gestational age in utero level indicates the patient is at an increased risk of developing a complication of preterm birth. The complications of preterm birth include retinopathy of prematurity, developmental delay, mental retardation, bronchopulmonary dysplasia, and intraventricular hemorrhage.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: December 5, 2006
    Assignee: Children's Medical Center Corporation
    Inventors: Lois Smith, Ann Hellström
  • Determination of risk and treatment of complications of prematurity
    Publication number: 20040053838
    Abstract: In one aspect of the present invention there is provided a method for determining the risk of developing a complication of preterm birth in a patient born before 40 weeks of gestation or weighing 10% less than the average for the patient's gestational age. The method involves measuring serum IGF-I and/or IGF-I binding protein levels after birth of the patient to obtain an IGF-I or IGF-I binding protein level; and correlating said IGF-I or IGF-I binding protein level with an in utero baseline level of IGF-I or IGF-I binding protein based on gestational age matched mean levels in utero, wherein an IGF-I or IGF-I binding protein level below the mean gestational age in utero level indicates the patient is at an increased risk of developing a complication of preterm birth. The complications of preterm birth include retinopathy of prematurity, developmental delay, mental retardation, bronchopulmonary dysplasia, and intraventricular hemorrhage.
    Type: Application
    Filed: May 28, 2003
    Publication date: March 18, 2004
    Inventors: Lois Smith, Ann Hellstrom